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Abstract RT-PCR experiments on RNA from K562 and
HepG2 cells and from human placenta led to the isolation of a
novel cDNA, a further alternative splicing product of the primary
transcript of low Mr phosphotyrosine phosphatase (LMW-PTP),
already known to produce isoforms 1 and 2. This new transcript
represents 15^20% of the total LMW-PTP mRNA in the cell.
This novel cDNA codifies for a protein that we have named SV3
(splicing variant 3): the deduced protein sequence presents the
first 49 residues identical to those of isoform 1, followed by 24
unrelated amino acids, due to a frameshift introduced at the novel
exon-exon boundary. The SV3 protein, expressed in E. coli is
enzymatically inactive, most probably because unfolded, as
suggested by far-UV circular dichroism (CD) experiments.
SV3 protein appears to possess the characteristics of an
unstructured polypeptide chain lacking the packing of side chain
residues and the secondary structure level that are typical of
globular proteins. This protein could represent an inactive variant
of the human LMW-PTP.
z 1998 Federation of European Biochemical Societies.
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1. Introduction
Protein tyrosine phosphorylation plays a key role in the
regulation of many cellular processes in eukaryotes such as
cellular metabolism, proliferation, di¡erentiation and onco-
genic transformation [1]. While activation of protein tyrosine
kinases (PTKs) appears to be a mandatory prerequisite for
cell growth stimulation, the phosphorylated state of a protein
in the cell is the result of a balance of kinase and phosphatase
activity: a heterogeneous family of protein tyrosine phospha-
tases (PTPases) has been proposed as key regulatory elements
of cellular phosphorylation levels [2]. There is evidence that
PTKs and PTPases cooperate in cell growth control [3].
Low Mr phosphotyrosine phosphatase (LMW-PTP) is an
18-kDa cytosolic enzyme widely distributed in eukaryotic
cells. It does not share signi¢cant sequence homology with
the other two classes of PTPases, with the only important
exception of the C X5 R motif, typical of the active site of
all these enzymes [4].
Two isoforms of LMW-PTP, isoforms 1 and 2 (IF1 and
IF2, respectively) have been isolated from various mammalian
tissues [5]. The two isoforms have been previously named
PTPfast and PTPslow (in human) and ACP1 and ACP2 (in
rat). Genomic DNA sequencing has shown that, in man,
6 exons are present in the primary transcript and that the
two isoforms originate through an alternative splicing mech-
anism [6], in which two exons (3F or 3S) are alternatively
incorporated in the mRNA sequence. As a consequence of
this phenomenon, two proteins (IF1 and IF2) are produced,
presenting di¡erences (41% of identity) only in the sequence
spanning residues 40^73, codi¢ed by exon 3 [7]. It is not yet
clear if the two isoforms play di¡erent physiological roles in
the cell.
Alternative splicing is a feature common to many di¡erent
genes. The ¢bronectin (FN) alternative splicing is one of the
best characterised: with this mechanism, several FN variants,
playing speci¢c roles, are produced [8]. In other cases the
presence of some variants derived from an alternative splicing
mechanism correlates with the tumoural phenotype, as dem-
onstrated for estrogen receptor [9].
Recently Chiarugi et al. [10] showed that LMW-PTP is
involved in the negative regulation of the mitogenic stimulus
starting from the activated PDGF receptor. The interaction
between LMW-PTP and the PDGF receptor results in the
dephosphorylation of activated PDGF-R phosphotyrosine(s)
and in a negative regulation of the mitogenic signal. It is very
likely that PDGF receptor is not the unique substrate of
LMW-PTP, since the involvement of LMW-PTP in the regu-
lation of the signals starting from the activated insulin recep-
tor has also been shown [11].
In this paper we describe the isolation of a novel LMW-
PTP mRNA originating via alternative splicing and the char-
acterisation of the corresponding polypeptidic product.
2. Materials and methods
2.1. Isolation of LMW-PTP SV3 cDNAs
Total RNA was isolated from placenta, HepG2 and K562 by
the guanidium isothiocyanate method [12]. RT-PCR experiments
were performed under standard conditions, using degenerated
oligonucleotides supplied by Pharmacia: 5P-TTTGT(C/G)TG(C/
T)CT(G/C)GG(G/C)AACAT(T/C)TG as ‘direct primer’ and 5P-
CC(A/G)- TA(A/G)TAGGGGTC(T/C)TC(A/G)AT(A/G)AT as ‘re-
verse primer’. PCR products were cloned into PCR II tailing vector
using TA Cloning System (Invitrogen). Primers 1D (5P-GTGTCTC-
GGCGCCTCTGC) and 1R (5P-ACCGACTGAGAAATGCAGGA)
were used for an RT-PCR experiment in order to clone the complete
SV3 coding sequence, together with the Bmix (5P-ACTTC-
CGGTGGGTCATTG) oligonucleotide for Southern blot experiments
in order to isolate the SV3 harbouring clones.
2.2. Determination of LMW-PTP IF1, IF2 and SV3 mRNA amounts
RT-PCR was performed in 100 Wl : 10 Wl of each sample was sep-
arated on 1.5% agarose gel, alkaline blotted to nylon Hybond N
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membrane ¢lter (Amersham) and separately hybridised with 32P-la-
belled oligonucleotide speci¢c for IF1, IF2 and SV3, respectively: BFf
(5P-CAACGTGGCTCATGGGA), BSr (5P-GAGAATTGGGT-
CATTGACAG) and Bmix as above. Each hybridisation was carried
out in standard conditions at a temperature of 5‡C below the calcu-
lated Tm. Hybridisation e⁄ciency was checked using identical quan-
tity of complementary DNA spotted on nitrocellulose. The probed
nitrocellulose ¢lters were exposed to X-ray ¢lm and the relative bands
acquired by UMAX VISTA Speedy scanner were quanti¢ed by com-
puter program NIH-IMAGER 1.61 run on a Macintosh Performa
6500.
2.3. Cloning and expression of the new LMW-PTP
The SV3 coding sequence was cloned in frame with glutathione S-
transferase in the pGEX-2T bacterial expression vector (Pharmacia).
The recombinant fusion protein was puri¢ed from the transformed E.
coli TB1 strain and digested with thrombin in order to obtain the SV3
isoform alone, as already described [13].
2.4. Equilibrium dialysis experiments
Equilibrium dialysis was performed using the apparatus described
by Reinard and Jacobsen [14]. As already described [15], 250 WM of
recombinant IF1, IF2 or SV3 of LMW-PTP were separately placed in
one of the two di¡erent compartments. After the equilibrium was
reached, the radioactivity was measured in each compartment. Scatch-
ard analysis of the data was performed as previously reported [16].
2.5. Circular dichroism
CD experiments were performed on a Jasco Model J720 spectro-
polarimeter equipped with a thermostated cell holder. Far UV spectra
were recorded at 25‡C in 50 mM acetate bu¡er, pH 5.5, at a protein
concentration of 0.06 mg/ml using a 0.5-cm path-length quartz cell
[17].
2.6. Urea titration curves
Urea titration curves were obtained at 25‡C by a spectro£uorimeter
Perkin Elmer LS 50 B. The £uorescence of 30 independent samples,
with di¡erent urea concentrations, containing 0.01 mg/ml of protein in
50 mM acetate bu¡er, pH 5.5, was recorded by using excitation and
emission wavelengths of 280 and 340 nm [18].
3. Results
3.1. Isolation of LMW-PTP SV3 cDNA
Human LMW-PTP is known to be present in two isoforms
originating by an alternative splicing process of a common
primary transcript of a single gene [6]. At the beginning of
this work we were interested in searching for di¡erent human
cDNA products that could codify for LMW-PTP-like pro-
teins, sharing common characteristic sequences, like those al-
ready recognised to be important for the catalysis. For this
purpose two degenerate oligonucleotides (‘direct’ and ‘re-
verse’) were prepared with sequences corresponding to the
parts of the protein very well conserved through evolution;
the two oligonucleotides were then used for an RT-PCR ex-
periment on total RNA from human placenta. This experi-
ment led to the isolation of a new LMW-PTP cDNA species,
30 bases longer with respect to the already known fast (IF1)
and slow (IF2) isoform cDNAs.
In order to obtain the entire coding region of this new
mRNA, ampli¢cation was performed with two primers com-
plementary to the beginning and to the end of the coding
sequence (1D and 1R); DNA sequencing of the product of
this PCR experiment led to the determination of the entire
coding sequence of this putative new LMW-PTP. Inspection
of the cDNA sequence, presented in Fig. 1, panel A, revealed
that much likely this new mRNA species is derived from an
alternative splicing phenomenon of the same LMW-PTP pri-
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Fig. 1. A: The coding sequence of SV3. Underlined: amino acids of the catalytic loop and triplets codifying for the ¢rst 10 amino acids of the
IF1 speci¢c sequence deriving from the 3F exon (see text). In bold: nucleotide sequence deriving by the 3S exon, together with the deduced
protein sequence. B: Proposed splicing mechanism producing the SV3 mRNA. The cryptic splicing site sequence, representing a possible addi-
tional acceptor site, is indicated.
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mary transcript that produces also the IF1 and IF2 mRNAs;
for this reason we have named this new LMW-PTP ‘splicing
variant 3P’ (SV3). While in the case of IF1 and IF2 exon 3F or
exon 3S are alternatively incorporated in the mRNA se-
quence, SV3 LMW-PTP mRNA contains the ¢rst 30 bases
of the 3F exon and the entire 3S exon sequence. After this
point the splicing mechanism follows the same pattern of IF1
and IF2. The result is that SV3 mRNA is 30 bases longer with
respect to IF1 and IF2 transcripts. Analysis of the cDNA
sequence revealed that this splicing mechanism introduces a
frame shift in correspondence to the 3F/3S-exon boundary. As
a consequence of this fact, the deduced SV3 protein sequence
is identical to the IF1 isoform up to the 49th residue; after
that residue the sequence totally diverges from that of IF1 and
arrives to an end in correspondence to a stop codon, giving a
73 amino acids long polypeptide, with a calculated Mr of
7676.8 Da. In Fig. 1, panel B, the probable splicing mecha-
nism generating the SV3 isoform is described; analysis of the
DNA sequence revealed the presence of a putative splice site
within the 3F exon sequence (as indicated in the ¢gure) that
could represent an additional donor site in the splicing mech-
anism leading to the production of the SV3 mRNA.
3.2. Evaluation of the di¡erent LMW-PTP mRNA levels
The relative amounts of IF1, IF2 and SV3 mRNAs were
evaluated in human placenta and in di¡erent human cell lines.
RT-PCR experiments were performed on total RNA, fol-
lowed by Southern blot hybridisation of the RT-PCR prod-
ucts with primers speci¢c for every single isoform (BFr, BSd
and Bmix for IF1, IF2 and SV3, respectively). In the RT-PCR
experiments a pair of oligonucleotides was used, the ¢rst one
(1D) complementary to a sequence immediately upstream the
ATG start codon and the second (1R) complementary to a
sequence 50 nucleotides after the stop codon; these sequences
are common to all isoforms, so that the use of 1D and 1R
oligonucleotides allows the ampli¢cation of all isoforms. In
this way the relative amount of the di¡erent products ob-
tained with RT-PCR will be proportional to the relative
amount of the mRNA of each isoform in the starting materi-
als. The experiments were performed on total RNA puri¢ed
from human placenta and from three di¡erent human cell
lines: HepG2 (hepatoma), K562 (erythroleukemia) and
HL60 (promyelocytic leukemia). The results are shown in
Fig. 2, expressed as relative amount of every single mRNA
species with respect to the total LMW-PTP mRNA (consid-
ered as 100%). In all cases examined the SV3 mRNA repre-
sents 15^20% of the total LMW-PTP mRNA. These results
indicate that SV3 mRNA could always be present in the cell
as a further product of the alternative splicing of the LMW-
PTP gene transcript, although at a lower extent with respect
to IF1 and IF2 mRNAs.
3.3. Expression and characterisation of the SV3 protein
The SV3 coding sequence was cloned in pGEX-2T vector
and expressed in E. coli. The protein was expressed as a fusion
with glutathione-S-transferase and then puri¢ed as native
form; SDS-PAGE analysis con¢rmed that this product has
an approximate molecular weight of 7.7 kDa, consistent
with the calculated size of the polypeptide. Routinely, about
2 mg/l of the protein was obtained. This quite low yield is due
to a partial precipitation of the protein, probably as a conse-
quence of its high hydrophobicity.
In order to gain insight into the structure of the protein, the
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Fig. 3. A: The far UV CD spectra of SV3 and of denatured and
native IF1 LMW-PTP. The spectra were acquired at 25‡C in 50 mM
acetate bu¡er, pH 5.5. Denaturation of IF1 was performed in 9.6 M
urea. B: The urea titration curve of SV3 (a), SV3 in the presence
of Pi (U) and IF1 LMW-PTP (b) monitored by intrinsic £uores-
cence emission (excitation at 280 nm, emission at 340 nm). The urea
titration curve was recorded at 25‡C. The SV3 data were linearly ¢t-
ted, whereas the solid line through the IF1 data represents the result
of the ¢tting procedure of Santoro et al. [22], characteristic of a
two-state transition. The protein concentration was 0.01 mg/ml.
Fig. 2. Determination of the level of the mRNA speci¢c for each
LMW-PTP isoform. RT-PCR products, generated with primers
complementary to sequences common to all LMW-PTP mRNAs,
were used for Southern blot analysis, performed with primers specif-
ic for each mRNA species. Quantitation was obtained by computer
program NIH-IMAGER 1.61. Quantities are expressed as percent-
age of the total LMW-PTP transcript. Sources of the di¡erent RNA
are indicated.
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far-UV CD spectrum of the SV3 LMW-PTP was acquired
and appeared to be typical of a denatured protein, the molar
ellipticity being very low in the far-UV region between 200
and 250 nm. Moreover, the far-UV CD spectrum of the SV3
LMW-PTP is very similar to that of IF1 denatured in 9.6 M
urea and very di¡erent to that of native IF1 (Fig. 3, panel A).
In the urea titration curve of SV3, the £uorescence was found
to increase linearly with urea concentration without any visi-
ble transitions. This phenomenon is usual for unfolded pro-
teins [17] and although a linear relationship is also character-
istic of native proteins, it is very unlikely that such proteins
maintain their fully folded conformation up to 9 M urea. In
the same experiment the IF1 form exhibits a normal £uores-
cence-detected transition between 3 and 5 M urea, as shown in
Fig. 3, panel B, which is suggestive of a urea-induced denatu-
ration process from a highly structured protein. The fact that
this denaturation process is not evident in SV3 LMW-PTP
strongly supports the hypothesis that the protein is unfolded
even in the absence of denaturant. It should be in fact under-
lined that while IF1 and IF2 undergo nearly total refolding
after the removal of the denaturant agent, this is not true for
SV3, which in the same conditions does not show any change
in its unfolded conformation.
LMW-PTP is known to bind speci¢cally the inorganic
phosphate ion [15]. Generally the speci¢c binding of ligands
is a powerful expedient to stabilise the native form of a pro-
tein [18]. The urea titration curve was then repeated in the
presence of 20 mM inorganic phosphate as an attempt to
detect the unfolding transition upon adding denaturant. The
persistent linearity of the plot still suggests the absence of any
residual structure even in stabilising conditions as shown in
Fig. 3, panel B.
Because of the fact that the catalytic loop characteristic of
LMW-PTP (residues 12^18) is also present in SV3, determi-
nation of the enzymatic activity of this isoform was per-
formed, using pNPP as a substrate; the protein showed no
measurable enzymatic activity. Moreover, in order to inves-
tigate whether SV3 could represent a naturally occurring
dominant negative variant of LMW-PTP, its possible phos-
phate binding capacity was evaluated; this is a main feature of
LMW-PTP, essentially due to the presence in the catalytic
loop of the Arg18 residue, present also in SV3. Equilibrium
dialysis experiments were performed using [32P]-inorganic
phosphate, a competitive inhibitor of LMW-PTP. As far as
IF1 or IF2 is concerned, a dissociation constant of about 0.5
mM was calculated by Scatchard analysis, in agreement with
previous data [16]. Similar experiments performed with SV3
did not allow the calculation of any a⁄nity constant, demon-
strating that SV3, in contrast with IF1 and IF2, is not able to
bind the substrate.
4. Discussion
In this paper we describe for the ¢rst time the character-
isation of SV3, a new human LMW-PTP variant. SV3 mRNA
clearly originated by an alternative splicing mechanism on the
same primary transcript also generating the IF1 and IF2
mRNAs (Fig. 1, panel B).
The SV3 mRNA is quite abundant in human placenta and
in di¡erent human cell lines that we have tested (Fig. 2).
Investigating the levels of the di¡erent mRNAs in K562 cells
we found that IF1 and IF2 represent 50 and 30% of the
LMW-PTP transcripts, respectively (SV3 being the residual
20%). We have noticed that the results concerning IF1 and
IF2 are partially in contrast with those of Tailor et al. [19],
where no IF1 is detected; this discrepancy could possibly be
due to di¡erences in distinct clones of K562 cells.
Recently we have cloned the murine LMW-PTP cDNA
(manuscript in preparation). RT-PCR analysis performed on
RNA from several di¡erent mouse tissues never demonstrated
the presence of the SV3 transcripts, probably due to the ab-
sence, in the mouse LMW-PTP mRNA, of the cryptic splicing
site that we ¢nd in the human 3F exon.
SV3 protein was expressed in E. coli ; the protein appeared
to be enzymatically inactive and not able to binding the sub-
strate, most probably because the protein is unfolded. In fact
SV3 has the characteristics of an unstructured polypeptide
chain lacking the cooperative secondary and tertiary structure
possessed by the native 18-kDa IF1. The absence of the long
C-terminal fragment in SV3 is most probably responsible for
the lack of su⁄cient conformational free energy to induce any
level of structure in this protein. The fact that SV3 does not
acquire any folded conformation after removal of high urea
concentrations, in contrast to what is observed for IF1, sup-
ports the idea that the protein could have the same unfolded
conformation also in the cell. On the other hand, it is di⁄cult
to evaluate whether the lack of enzymatic activity of SV3 is
only due to the absence of protein structure or rather to the
fact that SV3, although presenting the catalytic loop, lacks
several amino acids that have been demonstrated to partici-
pate to the catalysis in the active isoforms of LMW-PTP. In
fact it has been demonstrated that Asp129 is also involved in
the catalytic mechanism [16], as well as His66 and His72 [20].
Moreover, the role of Tyr131 and Tyr132 is still under discus-
sion; these two sites, necessary for a correct enzymatic activity
can also undergo phosphorylation, causing enzyme activation
[19]. Taken together, all these results suggest the possibility
that SV3, once synthesised, has no enzymatic activity in the
cell. It should be underlined that the protein is very hydro-
phobic and, possibly, in unfolded conformation. All these
¢ndings make possible the hypothesis that SV3, once pro-
duced, may be promptly degraded in the cell. The fact that
the SV3 mRNA isoform is abundantly expressed in all the
cells or tissues we have tested leaves open the possibility
that this isoform could play other roles in the cell, di¡erent
from those of IF1 and IF2.
Recently it has been proposed that many protein tyrosine
phosphatases may act as tumour suppressors [21], namely
those acting as negative regulators of cell proliferation. This
seems to be the case for LMW-PTP [10], and we could hy-
pothesise that a reduction of active LMW-PTP concentration
in the cell might lead to cell proliferation. A mechanism that
could control such levels might be a di¡erent regulation of the
relative abundance of the three mRNA isoforms generated by
alternative splicing. A switch towards an increased production
of SV3 mRNA could result in a reduction of active enzyme
and lead to cell proliferation increase. This hypothesis is also
suggested by the fact that variations of alternative splicing
patterns have already been correlated with tumour [9].
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